Fjarde AP Fonden Fourth Swedish National Pension Fund cut its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 8.2% during the first quarter, Holdings Channel reports. The fund owned 14,191 shares of the specialty pharmaceutical company’s stock after selling 1,272 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Jazz Pharmaceuticals were worth $2,029,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Kornitzer Capital Management Inc. KS lifted its holdings in Jazz Pharmaceuticals by 0.5% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 17,378 shares of the specialty pharmaceutical company’s stock valued at $2,154,000 after acquiring an additional 85 shares during the last quarter. First Hawaiian Bank raised its position in Jazz Pharmaceuticals by 42.2% in the fourth quarter. First Hawaiian Bank now owns 320 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 95 shares during the period. Advisor Group Inc. raised its position in Jazz Pharmaceuticals by 3.3% in the fourth quarter. Advisor Group Inc. now owns 3,755 shares of the specialty pharmaceutical company’s stock valued at $465,000 after purchasing an additional 120 shares during the period. Comerica Bank raised its position in Jazz Pharmaceuticals by 1.0% in the fourth quarter. Comerica Bank now owns 12,103 shares of the specialty pharmaceutical company’s stock valued at $1,512,000 after purchasing an additional 123 shares during the period. Finally, Carroll Financial Associates Inc. raised its position in Jazz Pharmaceuticals by 166.7% in the first quarter. Carroll Financial Associates Inc. now owns 200 shares of the specialty pharmaceutical company’s stock valued at $28,000 after purchasing an additional 125 shares during the period. Hedge funds and other institutional investors own 94.25% of the company’s stock.

Jazz Pharmaceuticals stock opened at $128.65 on Wednesday. Jazz Pharmaceuticals PLC has a twelve month low of $113.52 and a twelve month high of $184.00. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.42 and a current ratio of 3.57. The firm has a market cap of $7.51 billion, a PE ratio of 10.51, a P/E/G ratio of 1.08 and a beta of 1.16.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $3.16 by $0.51. Jazz Pharmaceuticals had a return on equity of 26.20% and a net margin of 23.64%. The business had revenue of $508.19 million for the quarter, compared to analyst estimates of $466.55 million. During the same quarter in the prior year, the company earned $2.98 earnings per share. The company’s revenue was up 14.3% on a year-over-year basis. Analysts predict that Jazz Pharmaceuticals PLC will post 13.19 EPS for the current year.

A number of analysts have issued reports on the company. BMO Capital Markets boosted their target price on Jazz Pharmaceuticals from $199.00 to $206.00 and gave the company an “outperform” rating in a research report on Wednesday, February 27th. Wells Fargo & Co set a $162.00 target price on Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 19th. SunTrust Banks assumed coverage on Jazz Pharmaceuticals in a research report on Tuesday, March 19th. They issued a “buy” rating and a $163.00 target price on the stock. Mizuho reissued a “hold” rating and issued a $147.00 target price (up previously from $137.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 27th. Finally, Cowen reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 13th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $182.71.

In other news, EVP Suzanne Sawochka Hooper sold 6,666 shares of the company’s stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $140.00, for a total transaction of $933,240.00. Following the sale, the executive vice president now owns 40,401 shares of the company’s stock, valued at $5,656,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Matthew P. Young sold 1,916 shares of the company’s stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $131.46, for a total value of $251,877.36. The disclosure for this sale can be found here. Insiders have sold 11,668 shares of company stock worth $1,606,567 in the last ninety days. Corporate insiders own 3.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/fjarde-ap-fonden-fourth-swedish-national-pension-fund-sells-1272-shares-of-jazz-pharmaceuticals-plc-jazz/3001819.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: What are Bollinger Bands?

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.